<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An activating 1849G&gt;T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Its role in other hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The mutation was frequent in <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) (86%) and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (95%) but less prevalent in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with an antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> or <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (5 [36%] of 14 patients) </plain></SENT>
<SENT sid="4" pm="."><plain>JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 2 (18%) of 11 patients with megakaryocytic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 7 (13%) of 52 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and 1 (1%) of 68 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>No mutation was found in Ph(+)<z:mp ids='MP_0005481'>CML</z:mp> (99 patients), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M0-M6 (28 patients), or <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (20 patients) </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that the JAK2 1849G&gt;T mutation is common in Ph(-) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> but not critical for transformation to the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of these diseases and that it is generally rare in aggressive <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
</text></document>